Related Experiment Video
Updated: May 21, 2026
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
New strategies for managing anemia of chronic kidney disease
Holger Schmid1, Helmut Schiffl, Stephan R Lederer
1KfH Nierenzentrum Munchen Laim, Munich, Germany. holger.schmid@lrz.uni-muenchen.de
Insights
Anemia treatment in chronic kidney disease (CKD) involves erythropoiesis-stimulating agents (ESAs) and iron. Current strategies focus on individualized dosing to balance quality of life and treatment risks.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Anemia is a common complication in chronic kidney disease (CKD), leading to adverse outcomes like increased mortality.
- Erythropoiesis-stimulating agents (ESAs) and iron are standard treatments for anemia in CKD patients.
- Lack of standardized dosing algorithms necessitates conservative, individualized treatment approaches.
Purpose of the Study:
- To review current evidence on hemoglobin targets for anemia in CKD and end-stage renal disease (ESRD).
- To discuss the market of biosimilar erythropoietins in Europe.
- To summarize novel therapeutic strategies and iron formulations for anemia management in CKD.
Main Methods:
- Review of large randomized trials on hemoglobin targets.
- Analysis of data from the European market for biosimilar erythropoietins.
- Clinical review of investigational agents (peginesatide, HIF-PH inhibitors) and new iron formulations (ferumoxytol, iron (III)-carboxymaltose).
Main Results:
- Current recommendations favor partial anemia correction with individualized ESA and iron dosing.
- Biosimilar erythropoietins are increasingly available in the European market.
- Novel therapies and high-dose iron formulations offer new avenues for anemia management.
Conclusions:
- CKD anemia treatment strategies are becoming more complex.
- Balancing patient quality of life with treatment risks is a critical challenge in nephrology.
- Individualized treatment plans considering novel agents and formulations are essential.
Abstract:
Anemia is a prevalent and premature comorbidity in chronic kidney disease (CKD) and associated with multiple adverse clinical consequences including increased mortality. Today Erythropoiesis-stimulating agents (ESAs), together with iron supplementation, are the cornerstones of therapy for correcting anemia in CKD patients. As no generally accepted dosing algorithms for these agents exist, current recommendations prefer a partial but not complete anemia correction thereby favoring a more conservative and individualized ESA and iron dosing. Here we discuss in detail current evidence derived from large randomized trials about the proposed hemoglobin targets to aim at in CKD and End-Stage renal disease patients and report recent data from the thriving European market of biosimilar erythropoietins. We summarize promising investigational strategies including peginesatide and prolyl hydroxylase inhibitors for stabilization of the hypoxia inducible factor and provide a clinical review of novel high dose iron formulations like ferumoxytol or iron (III)-carboxymaltose. Taking these findings together, treatment strategies for anemia of CKD have got considerably more complicated so that a careful balance between maximization of patient`s quality of life while minimizing all risks associated with anemia treatment has become a major task of current nephrology.
Related Concept Videos
01:18Chronic Kidney Disease IV: Nursing Management
01:28Chronic Kidney Disease III: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care
01:16Kidney Transplant III: Nursing Management
01:22Acute Kidney Injury VI: Nursing Management
01:25Peritoneal Dialysis III: Nursing Management